Biotech | April 22, 2022
Terran Biosciences announces licensing deal with Sanofi
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Subscribe To Our Newsletter & Stay Updated
